

Ministry of Health

Health Programs and Delivery Division

Drug Submission Status

Report for April 2024

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an HPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Mylan Pharmaceuticals ULC.	Glatiramer Acetate Injection	Copaxone	GLATIRAMER ACETATE	20 mg/mL	subcutaneous solution	02541440
Sanis Health Inc.	Olopatadine 0.2%	Pataday	OLOPATADINE HCl	0.2 % w/v	ophthalmic solution	02541653
Taro Pharmaceuticals Inc.	Taro-Posaconazole	Posanol	POSACONAZOLE	100 mg	DR tablet	02543311
Sivem Pharmaceuticals	Sumatriptan	Imitrex	SUMATRIPTAN SUCCINATE	50 mg	tablet	02546035
Sivem Pharmaceuticals	Sumatriptan	Imitrex	SUMATRIPTAN SUCCINATE	100 mg	tablet	02546043